行政院衛生署 - http://www.doh.gov.tw/statistic 。
鄭智勇, 林繼昌 編著。1991年。《大腸直腸癌之病理分類、分期與預後》。國防醫學 第十二卷第三期;217-221。李祥, 賴世偉, 黃金財 編著。2001年。《大腸直腸癌》。基層醫學 第十六卷第八期:192-198。馬克 . 波恰品醫師 (Mark Bennett Pochapin. M. D.) 著《What your doctor may not tell you about colorectal cancer》, 鄭清榮譯 《大腸癌診療室》。 台北,原水文化,2005年。
Astler, V. B., and Coller, F. A. (1954). The prognosis significant of direct extension of carcinoma of the colon and rectum. Ann. Surg. 139:846-851.
Angelopoulou, K., Stratis, M., and Diamandis, E. P. (1997). Humoral immune response against p53 protein in patients with colorectal carcinoma. Int. J. Cancer. 70:46-51.
Abeloff. (2000). Churchill livingstone. Clin. Oncol. 2nd ed. New York. 1611-1617.
Anwar, S., Frayling, I. M., and Scott, N. A. (2004). Systematic review of genetic influences on the prognosis of colorectal cancer. Br. J. Surg. 91:1275-1291.
Agudo, R., Arias, A., Pariente, N., Perales, C., Escarmis, C., Jorge, A., Marina, A., and Domingo, E. (2008). Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 382:652-666.
Bast RC, Jr., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H. Jr., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., Somerfield, M. R., and American Society of Clinical Oncology Tumor Markers Expert Panel. (2001). 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19:1865-1878.
Brichory, F. M., Misek, D. E., Yim, A. M., Krause, M. C., Giordano, T. J., Beer, D. G., and Hanash, S. M. (2001). An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 98:9824-9829.
Broll, R., Duchrow, M., Oevermann, E., Wellm, C., Schwandner, O., Schimmelpenning, H., Roblick, U. J., Bruch, H. P., and Windhovel, U. (2001). p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int. J. Colorectal Dis. 16:22-27.
Bergmann, U., and Beger, H. G. (2003). Endoscopic mucosal resection for advanced non-polypoid colorectal adenoma and early stage carcinoma. Surg. Endosc. 17:475-479.
Bai, X. F., Ni, X. G., Zhao, P., Liu, S.M., Wang, H.X., Guo, B., Zhou, L. P., Liu, F., Zhang, J.S., Wang, K., Xie, Y. Q., Shao, Y. F., and Zhao, X. H. (2004). Overexpression of annexin I in pancreatic cancer and its clinical significance. World J. Gastroenterol. 10:1466-1470.
Bijnsdorp, I. V., Comijn, E. M., Padron, J. M., Gmeiner, W. H., and Peters, G. J. (2007). Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol. Rep. 18:287-291.
Brody, J. D., Goldstein, M. J., Czerwinski, D. K., and Levy, R. (2009). Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood. 113:85-94.
Chen, T. H., Yen, M. F., Lai, M. S., and Koong, S. L. (1999). Evaluation of a selective screening for colorectal carcinoma: The Taiwan Multicenter Cancer Screening (TAMCAS) project. Cancer. 86:1116-1128.
Choi, S., Kobayashi, M., Wang, J., Habelhah, H., Okada, F., Hamada, J., Moriuchi, T., Totsuka, Y., and Hosokawa, M. (2000). Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin. Exp. Metastasis. 18:45-50.
Chen, L. T., and Whang-Peng, J. (2004). Current status of clinical studies for colorectal cancer in Taiwan. Clin. Colorectal Cancer. 4:196-203.
Duffy, M. J., Van-Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., and Topolcan, O. (2007). Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer. 43:1348-1360.
Duncan, R., Carpenter, B., Main, L. C., Telfer, C., and Murray, G. I. (2008). Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer. 98:426-433.
Fan, C. W., Fan, H. A., Hsu, S. H., Chan, C. C., Chen, S. Y., Hsu, Y. H., and Chan, E. C. (2004). An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer. Cancer Lett. 214:181-188.
Fischer, J. A., Muller-Weeks, S., and Caradonna, S. J. (2008). Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase. Cancer Res. 66:8829-8837.
Gorlick, R., and Bertino, J. R. (1999). Drug resistance in colon cancer. Semin. Oncol. 26:606-611.
Grothey, A., and Schmoll, H. J. (2001). New chemotherapy approaches in colorectal cancer. Curr. Opin. Oncol. 13:275-286.
Gerke, V., and Moss, S. E. (2003). Annexins: from structure to function. Physiol. Rev. 82:331-371.
Gerke, V., Creutz, C. E., and Moss, S. E. (2005). Annexins: linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. 6:449-461.
Gmeiner, W. H. (2005). Novel chemical strategies for thymidylate synthase inhibition. Curr. Med. Chem. 12:191-202.
Grem, J. L. (2005). Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Semin. Oncol. 32:120-127.
Galmarini, C. M., Warren, G., Kohli, E., Zeman, A., Mitin, A., and Vinogradov, S. V. (2008). Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol. Cancer Ther. 7:3373-3380.
Han, E. K., Tahir, S. K., Cherian, S. P., Collins, N., and Ng, S. C. (2000). Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer. 83:83-88.
Hayes, M. J., and Moss, S. E. (2004). Annexins and disease. Biochem. Biophys. Res. Commun. 322:1166-170.
Hartmann, T. B., Bazhin, A. V., Schadendorf, D., and Eichmuller, S. B. (2005). SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int. J. Cancer. 114:88-93.
Haller, D. G., Rothenberg, M. L., Wong, A. O., Koralewski, P. M., Miller, W. H. Jr., Bodoky, G., Habboubi, N., Garay, C., and Olivatto, L. O. (2008). Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J. Clin. Oncol. 26:4544-4550.
Hamilton, S. R. (2008). Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod. Pathol. 21:S23-S30.
Hind, D., Tappenden, P., Tumur, I., Eggington, S., Sutcliffe, P., and Ryan, A. (2008). The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 12:iii-ix, xi-162.
Kourie, J. I., and Wood, H. B. (2000). Biophysical and molecular properties of annexin-formed channels. Prog. Biophys. Mol. Biol. 73:91-134.
Kunth, A., Jager, D., and Jager, E. (2000). Cancer immunotherapy in clinical oncology. Cancer Chemother. Pharmacol. 46:S46-S51.
Koziol, J. A., Zhang, J. Y., Casiano, C. A., Peng, X. X., Shi, F. D., Feng, A. C., Chan, E. K., and Tan, E. M. (2003). Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. 9:5120-5126.
Kocer, B., McKolanis, J., and Soran, A. (2006). Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC. Gastroenterol. 6:4.
Kuespert, K., Pils, S., and Hauck, C. R. (2006). CEACAMs: their role in physiology and pathophysiology. Curr. Opin. Cell Biol. 18:565-571.
Kim, S. Y., Hong, Y. S., Kim, B. C., Park, J. W., Chio, H. S., Jeong, S. Y., Kim, D. Y., Hong, C. W., Sohn, D. K., and Jung K. H. (2008). A phase II sdudy of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. Invest. New Drugs. DOI 10.1007/s10637-008-9177-5.
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr., and ASCO. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24:5313-5327.
Lim, L. H., and Pervaiz, S. (2007). Annexin 1: the new face of an old molecule. FASEB. J. 21:968-975.
Ladd, J., Lu, H., Taylor, A. D., Goodell, V., Disis, M. L., and Jiang, S. (2008). Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf. B. Biointerfaces. COLSUB-3467, No. of pages 6.
Moertel, C. G., O’Fallon, J. R., Go, V. L., O’Connell, M. J., and Thynne, G. S. (1986). The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 58:603-610.
Marrelli, D., Roviello, F., De, S. A., and Farnetani, M. (1999). Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology. 57:55-62.
Munro, A. J., Lain, S., and Lane, D. P. (2005). P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br. J. Cancer. 92:434-444.
Montemurro, M., Achtari, L., Roth, A., Halkic, N., Luthi, F., Ozsahim, M., Denys, A., Bauer, J., Demartines, N., and Leyvraz, S. (2008). Systemic treatment of metastatic colorectal cancer. Rev. Med. Suisse. 21:1254-1257.
Nazli, O., Bozdag, A. D., Tansug, T., and Kir, R. (2000). The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology. 47:1750-1752.
Popat, S., Hubner, R., and Houlston, R. S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23:609-618.
Popat, S., Wort, R., and Houlston, R. S. (2006). Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC. Cancer. 6:150.
Pasetto, L. M., Falci, C., Rizzo, E., De Salvo, G. L., Gasparini, G., D’ Andrea, M., Bajetta, E., Platania, M., Alabiso, O., Miraqlia, S., Oniqa, F., Biason, R., Chetri, M. C., Fedele, P., Massara, G., Romaniello, I., Giordano, M., Luchena, G., Buzzi, F., Ricotta, R., Siena, S., and Monfardini, S. (2008). Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Res. 28:1813-1820.
Rand, J. H. (2000). The annexinopathies: a new category of diseases. Biochim. Biophys. Acta. 1498:169-173.
Renner, C., Trumper, L., and Pfreundschuh, M. (2000). Tumour vaccines: a new immunotherapeutic approach in oncology. Ann. Hematol. 79:651-659.
Rescher, U., and Gerke, V. (2004). Annexins-unique membrane binding proteins with diverse functions. J. Cell Sci. 117:2631-2639.
Rubin, P., and Hansen, J. T., ”TNM staging atlas” , Lippincott Williams & Wilkins, 2008.
Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., and Pfreundschuh, M. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA. 92:11810-11813.
Sahin, U., Tureci, O., and Pfreundschuh, M. (1997). Serological identification of human tumor antigens. Curr. Opin. Immunol. 9:709-716.
Schmoll, H. J., Buchele, T., Grothey, A., and Dempke, W. (1999). Where do we stand with 5-fluorouracil ? Semin. Oncol. 26:589-605.
Smith, T. J., Davidson, N. E., Schapira, D. V., and Grunfeld, E. (1999). American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J. Clin. Oncol. 17:1080-1082.
Scholzel, S., Zimmermann, W., Schwarzkopf, G., and Grunert, F. (2000). Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am. J. Pathol. 156:595-605.
Soussi, T. (2000). p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60:1777-1788.
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., Van Beveren, C., Marchese, A., Ferre, F., Duffy, C., Carlo, D. J., Sherman, L. A., Gold, D. P., and Sobol, R. E. (2002). Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin. Exp. Immunol. 129:99-106.
Storojeva, I., Boulay, J. L., and Heinimann, K. (2005). Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol. Rep. 14:241-249.
Suh, K. W., Kim, J. H., and Kim, Y. B. (2005). Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J. Gastrointest Surg. 9:336-342.
Sharma, M. R., Koltowski, L., Ownbey, R. T., Tuszynski, G. P., and Sharma, M. C. (2006). Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp. Mol. Pathol. 81:146-156.
Shimada, H., Kuboshima, M., Shiratori, T., Nabeya, Y., Takeuchi, A., Takagi, H., Nomura, F., Takiguchi, M., Ochiai, T., and Hiwasa, T. (2007). Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int. J. Oncol. 30:97-103.
Syed, S. P., Martin, A. M., Haupt, H. M., Arenas-Elliot, C. P., and Brooks, J. J. (2007). Angiostatin receptor annexin II in vascular tumors including angio-sarcoma. Hum. Pathol. 38:508-513.
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A. Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., Lenz, H. J., Borg, C., Middleton, G., Kroning, H., Luppi, G., Kisker, O., Zubel, A., Langer, C., Kopit, J., and Burris H. A. 3rd. (2008). EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:2311-2319.
Tung, J. Y., Chen, G. H., and Yeh, C. L. (1986). Colorectal cancer. J. Chin. Oncol. Soc. 2:11-16.
Thompson, J. A., Grunert, F., and Zimmermann, W. (1991). Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J. Clin. Lab. Anal. 5:344-366.
Tas, F., Aydiner, A., Topuz, E., and Yasasever, V. (2000). Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. J. Exp. Clin. Cancer Res. 19:477-481.
Tang, R., Ko, M. C., Wang, J. Y., Changchien, C. R., Chen, H. H., Chen, J. S., Hsu, K. C., Chiang, J. M., and Hsieh, L. L. (2001). Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer. 94:859-863.
Takahashi, Y., Takeuchi, T., Sakamoto, J., and Touge, T. (2003). The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study. Gastric Cancer. 6:142-145.
Toubi, E., and Shoenfeld, Y. (2007). Protective autoimmunity in cancer (review). Oncol. Rep. 17:245-251.
Tsujimoto, S., Fujimoto, K., Okajima, E., Ozono, S., Okajima, E., and Hirao, Y. (2008). 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil. Int. J. Clin. Oncol. 13:138-143.
Umar, A., Boland, C. R., and Terdiman, J. P. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96:261-268.
Van Kuilenburg, A. B. (2004). Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer. 40:939-950.
Vishwanatha, J. K., Salazar, E., and Gopalakrishnan, V. K. (2004). Absence of annexin I expression in B-cell non-Hodgkin’s lymphomas and cell lines. BMC. Cancer. 4:8.
Van, C. E., and Geboes, K. (2007). The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 21:1089-1108.
Vakhabova, J. V., Semenov, N. N., Dobrova, N. V., and Lichinitser, M. R. (2008). Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer. Bull. Exp. Biol. Med. 145:249-251.
Wu, K. L., and Cheng, T. C. (1983). Carcinoma of colon. Chin. Med. J. 32:378-381.
Wang, W. S., Lin, J. K., Chiou, T. J., Liu, J. H., Fan, F. S., Yen, C. C., Lin, T. C., Jiang, J. K., Yang, S. H., Wang, H. S., and Chen, P. M. (2000). Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn. J. Clin. Oncol. 30:12-16.
Wang, W. S., Lin, J. K., Chiou, T. J., Liu, J. H., Fan, F. S., Yen, C. C., Lin, T. C., Jiang, J. K., Yang, S. H., Wang, H. S., and Chen, P. M. (2002). CA 19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 49:160-164.
Westra, J. L., Plukker, J. T., and Buys, C. H. (2004). Genetic alterations in locally advanced stage II/III colon cancer: A search for prognostic markers. Clin. Colorectal Cancer. 4:252-259.
Wu, C. C., Chen, H. C., Chen, S. J., Liu, H. P., Hsieh, Y. Y., Yu, C. J., Tang, R., Hsieh, L. L., Yu, J. S., and Chang, Y. S. (2008). Identification of collapsing response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics. 8:316-332.
Zimmermann, U., Balabanov, S., Giebel, J., Teller, S., Junker, H., Schmoll, D., Protzel, C., Scharf, C., Kleist, B., and Walther, R. (2004). Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 209:111-118.
Zimmermann, U., Woenckhaus, C., Teller, S., Venz, S., Langheinrich, M., Protzel, C., Maile, S., Junker, H., and Giebel, J. (2007). Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome. Histol. Histopathol. 22:527-534.
Zhang, J. Y., Megliorino, R., Peng, X. X., Tan, E. M., Chen, Y., and Chan, E. K. (2007). Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J. Hepatol. 46:107-114.